Neuboron Therapy System (NTS) is a wholly owned subsidiary of Neuboron Medtech focused on development and commercialization of the NeuPexTM accelerator-based BNCT system. Neuboron Medtech was established in 2014 in Nanjing, China, and set up NTS in 2017 to pursue global markets. The company offers a BNCT total solution that includes an accelerator-based system, a treatment planning system, a Monte‑Carlo dose engine, and tumor‑targeting boron carriers, and it reports over 500 patented and IP‑protected technologies. NeuPexTM can deliver high‑quality neutron beams using low‑energy protons from electromagnetic or electrostatic accelerators, but it is not yet approved by China’s NMPA or the U.S. FDA. NTS is installing a NeuPexTM at the BNCT center of Xiamen Humanity Hospital (three treatment rooms) and plans to launch clinical trials in the second half of 2021. The company aims to expand global deployment and patient access through strategic partnerships and supply‑chain strengthening.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2020